Myomo Inc. (AMEX:MYO) is expected to report second quarter earnings results, after market close, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 1.27 per share.
Looking ahead, the full year loss are expected at $ 5.21 per share on the revenues of $ 4.69 million.
The Company Outlook
Revenue for 2Q20 are expected in a range of $ 0.60 million ~ $ 0.70 million
Click Here For More Historical Outlooks Of Myomo Inc.
Previous Quarter Performance
Myomo Inc. posted loss for the first quarter of $ 2.51 per share, from the revenue of $ 1.01 million. The quarterly revenues grew 21.69 percent compared with the same quarter last year. According to street consensus, MYO was expected to report 1Q20 loss of $ 2.06 per share from revenue of $ 0.85 million. The bottom line results missed street analysts by $ 0.45 or 21.84 percent, at the same time, top line results outshined analysts by $ 0.16 million or 18.82 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Myomo Inc.
Stock Performance
According to the previous trading day, closing price of MYO was $ 3.92, representing a 39.01 % increase from the 52 week low of $ 2.82 and a 90.2 % decrease over the 52 week high of $ 40.00.
The company has a market capital of $ 11.03 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”MYO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Myomo Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.myomo.com
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis used for the purpose of supporting a patients weak or deformed arm to enable and improve functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders.
